GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArgent Bio. Regulatory News (RGT)

Share Price Information for Argent Bio. (RGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.00
Bid: 20.00
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 2.00 (10.00%)
Open: 21.00
High: 21.00
Low: 21.00
Prev. Close: 21.00
RGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Notification

10 Apr 2024 16:30

RNS Number : 0885K
Argent Biopharma Limited
10 April 2024
 

 

Argent BioPharma Ltd

PDMR Notification

10 April 2024

ASX, LSE: RGT

 

Argent BioPharma Ltd ('Argent BioPharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in Argent BioPharma, and this notification is made in accordance the UK Market Abuse Regulations.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Amir Polak

2

Reason for the notification

 

(a)

Position

 

Chief Pharmaceutical Development Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Full name of entity

Argent BioPharma Limited

 

Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU0000326647

(c)

Nature of transaction

Disposal of Shares

(d)

Currency

Price

Volume

Total

AUD

0.43

200

86.00

AUD

0.43

3,300

1,419.00

AUD

0.44

2,000

880.00

Aggregated information

AUD

 

5,500

2,385.00

(e)

Date of transaction

 

8-10 April 2024

(f)

Place of transaction

 

On Market

 

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@argentbiopharma.co.uk

 

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6382 3390

info@argentbiopharma.co.uk

UK IR/PR Advisers 

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

argentbiopharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com 

About Argent BioPharma

 

Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGMDKGLGDZM
Date   Source Headline
23rd May 20248:00 amRNSChange of OTCQB Company Code
7th May 20247:00 amRNSTrading on the OTCQB and Appointment of CFO
30th Apr 20244:01 pmRNSPDMR Notification
30th Apr 20248:54 amRNSMarch 2024 Quarter Activity Report
15th Apr 20247:00 amRNSDr. Shlomo Sadoun Joins Advisory Board
10th Apr 20244:30 pmRNSPDMR Notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.